Skip to content

Live Events
Sign Up / Login

Live Events
Sign Up / Login

MEC Plus Full List View

By pinki@katapult.biz / February 16, 2025

MEC Plus

Speciality

Author / Speaker

Title

Type of Media

Events

Search Entries:

Clear

«
1
…
32
33
34
35
36
…
115
»

Locally Advanced NSCLC Chemotherapy / Targeted Therapy / Immunotherapy

Locally Advanced NSCLC Chemotherapy / Targeted Therapy / Immunotherapy

Surbhi Singhal, MD

Stage III NSCLC– Surgical/ Combined Modality

Stage III NSCLC– Surgical/ Combined Modality

Johannes R. Kratz, MD

Locally Advanced NSCLC- Radiation Therapy

Locally Advanced NSCLC- Radiation Therapy

Lucas Vitzthum, MD

Radiation in Early-Stage NSCLC

Radiation in Early-Stage NSCLC

Billy W. Loo, Jr., MD, PhD, FASTRO, FACR

Adjuvant / Neo-adjuvant Systemic Therapy

Adjuvant / Neo-adjuvant Systemic Therapy

Heather Wakelee, MD, FASCO

Surgery for Early-Stage NSCLC

Surgery for Early-Stage NSCLC

Luis A. Godoy, MD, MAS, FACS

Pulmonary – From Diagnostics to Therapeutics

Pulmonary – From Diagnostics to Therapeutics

Nicholas Stollenwerk, MD

Lung Cancer Screening / Tobacco Control

Lung Cancer Screening / Tobacco Control

Natalie Lui, MD, MAS

Update on T-Cell Lymphomas

Update on T-Cell Lymphomas

Juan Carlos Ramos, MD

Modern Challenges and New Options for B-cell NHL

Modern Challenges and New Options for B-cell NHL

Eduardo Sotomayor, MD

Most Relevant News in Multiple Myeloma in 2023

Most Relevant News in Multiple Myeloma in 2023

Sergio Giralt, MD, FACP, FASTCT

New Developments in CLL

New Developments in CLL

Javier Pinilla-Ibarz, MD, PhD

The Era of Antibody Drug Conjugates in NSCLC Targeting Her-2, CEACAM5, TROP-2, and MET

The Era of Antibody Drug Conjugates in NSCLC Targeting Her-2, CEACAM5, TROP-2, and MET

Jason Porter, MD

Most Relevant Data on Immunotherapy in Neo-Adjuvant, Adjuvant, and Metastatic NSCLC

Most Relevant Data on Immunotherapy in Neo-Adjuvant, Adjuvant, and Metastatic NSCLC

Luis E. Raez, MD, FACP, FCCP

Updates on Targeting ALK, ROS1 ,and RET in NSCLC

Updates on Targeting ALK, ROS1 ,and RET in NSCLC

Jessica Lin, MD

New Developments in EGFR and K-RAS Therapies in NSCLC

New Developments in EGFR and K-RAS Therapies in NSCLC

Edgardo S. Santos, MD, FACP

New Developments in Metastatic Breast Cancer: Immunotherapy and Novel Therapeutic Pathways

New Developments in Metastatic Breast Cancer: Immunotherapy and Novel Therapeutic Pathways

Joyce O’Shaughnessy, MD

Breast Cancer Update in Hormone Sensitive Breast Cancer

Breast Cancer Update in Hormone Sensitive Breast Cancer

Lauren Carcas, MD

Novel Frontiers in the Use of ctDNA in Oncology

Novel Frontiers in the Use of ctDNA in Oncology

Christian Rolfo, MD, PhD, MBA, Dr.hc.

Developments in Head and Neck Cancers Including Thyroid Malignancies

Developments in Head and Neck Cancers Including Thyroid Malignancies

Moises Harari-Turquie, MD

Gynecologic Malignancies: New Targeted Therapy-IO-Chemo Combinations

Gynecologic Malignancies: New Targeted Therapy-IO-Chemo Combinations

Ritu Salani, MD, MBA

Updates in Kidney and Bladder Cancers: Where we are with Immunotherapy and Precision Medicine?

Updates in Kidney and Bladder Cancers: Where we are with Immunotherapy and Precision Medicine?

Karine Tawagi, MD

Updates in Cholangiocarcinoma and Pancreas Cancer: What is new in Targeted Therapy or Immunotherapy?

Updates in Cholangiocarcinoma and Pancreas Cancer: What is new in Targeted Therapy or Immunotherapy?

Milind M. Javle, MD

Updates in Colorectal Cancer

Updates in Colorectal Cancer

Fernando de Zarraga, MD

Updates in Prostate Cancer: Combination Therapy Becoming the Best Approach?

Updates in Prostate Cancer: Combination Therapy Becoming the Best Approach?

Chandler Park, MD, FACP

Displaying 826 - 850 of 2,875

Post navigation

← Previous View

6619 South Dixie Highway #341
Miami, FL 33143

Phone: 305.663.1628
Email: info@meccinc.com

Userful Links

Live Events

Categories

About Us

Why Subscribe
About Us
Accreditation

© 2025 MEC Inc. All rights reserved | Digital Marketing by Katapult Marketing

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok